
Insmed (INSM): BRINSUPRI Launch Drives the Bull Case
Insmed is scaling quickly on the back of BRINSUPRI, with ARIKAYCE still contributing meaningful cash flow. The stock looks attractive for investors who can accept biotech execution risk, but valuation remains demanding.










